INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
X / Longevity science · observed profile

Matt Kaeberlein

Profile links Optispan. ORCID supports researcher identity, not platform control. GLP-1 commentary is relevant but is not peptide-only expertise. Affiliation and commercial-interest review remains incomplete.

Source record

Public profile ↗ · Identity / context source ↗

What this record does not establish

Inclusion is not endorsement of credentials, products, clinical claims or influence. No standardized engagement or practitioner-audience sample exists. Counts are not used to rank these accounts.

Checked 29 October 2026. Manual public snapshot; no authorized feed access.

THE MODERN DOSING WEEKLY

The peptide news
that changes your week.

Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.